This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia

This study has been completed.
Information provided by:
AB Foundation Identifier:
First received: September 28, 2005
Last updated: May 29, 2010
Last verified: May 2010
Cutaneous leishmaniasis is typically treated with the parenteral product pentavalent antimony. Miltefosine is an oral agent shown to be active for mucosal leishmaniasis due to L braziliensis in Bolivia and cutaneous leishmaniasis due to L panamensis in Colombia. This trial is intended to evaluate miltefosine for cutaneous leishmaniasis due to L braziliensis in Bolivia. Patients will be randomly assigned to miltefosine or pentavalent antimony. Standard dose regimens will be used for both drugs.

Condition Intervention Phase
Cutaneous Leishmaniasis Drug: miltefosine Drug: antimony Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia

Resource links provided by NLM:

Further study details as provided by AB Foundation:

Primary Outcome Measures:
  • cure rate

Estimated Enrollment: 80
Study Start Date: September 2005
Estimated Study Completion Date: September 2007

Ages Eligible for Study:   3 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Presentation: At least 1 lesion must be ulcerative. Parasitology: Parasitological confirmation of 1 lesion will be made by visualization or culture of leishmania from the biopsy or aspirate of the lesion.

Previous RX: No specific or putatively specific therapy for leishmaniasis (Sb, pentamidine, amphotericin B, imidazoles, allopurinol)

Other diseases: No concomitant diseases by history and by approximately normal complete blood counts (white blood count, hemoglobin, platelet count), values of liver transaminases (SGOT) and kidney function tests (creatinine).

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00233545

Puesto de Salud, Campamento OSCAR,
Palos Blancos,, Bolivia
Sponsors and Collaborators
AB Foundation
Principal Investigator: J Soto, MD FADER
  More Information Identifier: NCT00233545     History of Changes
Other Study ID Numbers: 01-2005
Study First Received: September 28, 2005
Last Updated: May 29, 2010

Keywords provided by AB Foundation:

Additional relevant MeSH terms:
Leishmaniasis, Cutaneous
Euglenozoa Infections
Protozoan Infections
Parasitic Diseases
Skin Diseases, Parasitic
Skin Diseases, Infectious
Skin Diseases
Antifungal Agents
Anti-Infective Agents
Antineoplastic Agents
Antiprotozoal Agents
Antiparasitic Agents processed this record on September 20, 2017